公开(公告)号：US20210161954A1

公开(公告)日：2021-06-03

申请号：US16498899

申请日：2018-03-30

Applicant: CELLECTIS SA

Inventor： Julianne Smith ,  Philippe Duchateau ,  Murielle Derrien

IPC: A61K35/17 ,  C07K16/28 ,  A61P35/02 ,  A61K31/365 ,  C07K14/705 ,  C07K14/725

Abstract: The present invention relates to an engineered immune cell endowed with a new CD22 Chimeric Antigen Receptors (CD22 CAR) with a deletion in the TRAC gene that is able to redirect said immune cell specificity and reactivity toward selected tumor cells. The engineered immune cells endowed with such CARs are particularly suited for treating relapsed refractory CD22 expressing cancers.

公开(公告)号：US12133867B2

公开(公告)日：2024-11-05

申请号：US18393322

申请日：2023-12-21

Applicant: CELLECTIS SA

Inventor： Julianne Smith ,  Phillippe Duchateau ,  Murielle Derrien

IPC: A61K35/17 ,  A61K31/365 ,  A61K39/395 ,  A61P35/02 ,  C07K14/705 ,  C07K14/725 ,  C07K16/28

Abstract: The present invention relates to an engineered immune cell endowed with CD22 Chimeric Antigen Receptors (CD22 CAR) with a deletion in the TRAC gene that is able to redirect immune cell specificity and reactivity toward selected tumor cells. The engineered immune cells endowed with such CARs are particularly suited for treating relapsed refractory CD22 expressing cancers.

公开(公告)号：US11944643B2

公开(公告)日：2024-04-02

申请号：US16498899

申请日：2018-03-30

Applicant: CELLECTIS SA

Inventor： Julianne Smith ,  Philippe Duchateau ,  Murielle Derrien

IPC: A61K35/17 ,  A61K31/365 ,  A61K39/395 ,  A61P35/02 ,  C07K14/705 ,  C07K14/725 ,  C07K16/28

CPC classification number: A61K35/17 ,  A61K31/365 ,  A61K39/39558 ,  A61P35/02 ,  C07K14/7051 ,  C07K14/70517 ,  C07K14/70578 ,  C07K16/2803 ,  C07K2317/34 ,  C07K2317/53 ,  C07K2317/622

Abstract: The present invention relates to an engineered immune cell endowed with CD22 Chimeric Antigen Receptors (CD22 CAR) with a deletion in the TRAC gene that is able to redirect immune cell specificity and reactivity toward selected tumor cells. The engineered immune cells endowed with such CARs are particularly suited for treating relapsed refractory CD22 expressing cancers.